Roche预测2026年的中位数数字销售和高位数数字收入增长,并引用了强劲的药物管道和临床结果。 Roche forecasts 2026 mid-single-digit sales and high-single-digit earnings growth, citing strong drug pipeline and clinical results.

Roche Holding AG以固定汇率预测2026年的中位数销售增长和高位数核心核心收入每股增长,并列举其大量新药和积极的晚期临床结果。 Roche Holding AG projects mid-single-digit sales growth and high-single-digit core earnings per share growth for 2026 on a constant exchange rate basis, citing its strong pipeline of new drugs and positive late-stage clinical results. 据该公司报告,2025年的收入为61.52亿瑞士法郎(80.07亿美元),按固定货币计算增长7%,核心EPS增至19.46瑞士法郎。 The company reported 2025 revenue of 61.52 billion Swiss francs ($80.07 billion), a 7% increase at constant currencies, with core EPS rising to 19.46 francs. 尽管对分析员的期望略微缺失,但Roche仍然有信心在有竞争力的行业中未来的表现。 Despite slightly missing analyst expectations, Roche remains confident in its future performance amid a competitive industry.